Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalSummaCare Bone Graft Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Bone and Tendon Graft Substitutes Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and authorization for bone grafts, tendon graft substitutes, osteogenic proteins, antibiotic beads, bone marrow injections, and related products used to enhance bone healing. It applies to SummaCare commercial and Medicare members; self-funded commercial groups should consult their plan documents.

    Policy Summary
    PayerSummaCare
    PolicyBone and Tendon Graft Substitutes Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionFor authorization, submit the planned procedure, graft or substitute product, and clinical information demonstrating that the applicable medical-necessity criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Specified medically necessary graft or substitute categories
    14 daysTibial fracture rhBMP-2 timing limit
    3+Multilevel fusion threshold
    ExperimentalUnlisted indications
    2Covered plan types
    3Evidence and guideline reference bases

    Covered Services and Medical Necessity

    FDA-Approved Bone Graft Materials

    FDA-approved bone graft materials are covered as medically necessary for enhancement of bone healing.

    ONE or more of the following FDA-approved bone graft materials

    • Autografts
    • Demineralized bone matrix (DBM)
    • Allograft-based products

    Infuse® rhBMP-2: Anterior or Posterior Cervical Fusion

    Infuse® Bone Graft (recombinant human bone morphogenetic protein-2 [rhBMP-2]) is considered medically necessary for anterior or posterior cervical fusion when ALL of the following criteria are met.

    ALL of the following

    • Member does not have any known contraindications, including pregnancy or hypersensitivity/allergy.
    • Performed for an associated approved spinal fusion.
    • Member has ONE of the following conditions that would place the individual at high risk of fusion failure without rhBMP-2

      • Neuromuscular scoliosis
      • Occipitocervical pathology

    Infuse® rhBMP-2: Stand-Alone ALIF

    Infuse® Bone Graft (rhBMP-2) is considered medically necessary for a stand-alone anterior lumbar interbody fusion (ALIF) when ALL of the following criteria are met.

    ALL of the following

    • Performed for an associated approved stand-alone anterior lumbar interbody fusion (ALIF).
    • The individual does not have any known contraindications, including pregnancy or hypersensitivity/allergy.
    • Member is skeletally mature.

    Infuse® rhBMP-2: PLF, PLIF, or TLIF

    Infuse® Bone Graft (rhBMP-2) is considered medically necessary for posterolateral lumbar fusion (PLF), posterior lumbar interbody fusion (PLIF), or transforaminal lumbar interbody fusion (TLIF) when ALL of the following criteria are met.

    ALL of the following

    • No known contraindications, including pregnancy or hypersensitivity/allergy.
    • Performed for an associated approved spinal fusion.
    • There is a high risk of fusion failure due to ONE or more of the following clinical scenarios

      • High risk for fusion failure using traditional autogenous bone grafting in a planned revision spinal fusion for pseudoarthrosis following previous failed spinal fusion.
      • High risk for fusion failure using traditional autogenous bone grafting in a spinal fusion in a compromised graft bed (e.g., prior radiation therapy).

    Infuse® rhBMP-2: Tibial Fractures

    Infuse® Bone Graft (rhBMP-2) is considered medically necessary in the surgical repair of an acute, open tibial shaft fracture when BOTH of the following criteria are met.

    ALL of the following

    • Fracture is stabilized with intramedullary (IM) nail fixation.
    • rhBMP-2 is applied within 14 days of the fracture.within 14 days

    PMMA or Calcium Antibiotic Beads

    PMMA antibiotic beads or calcium sulfate antibiotic beads are medically necessary when used in conjunction with intravenous antibiotics in the treatment of chronic osteomyelitis.

    ALL of the following

    • PMMA antibiotic beads or calcium sulfate antibiotic beads are used.
    • Used in conjunction with intravenous antibiotics.
    • Treatment is for chronic osteomyelitis.

    Bone Marrow Injections

    Bone marrow injections are medically necessary in the treatment of bone cysts (unicameral/simple).

    ALL of the following

    • Treatment is for a unicameral/simple bone cyst.

    Hydroxyapatite Bone Substitute

    Hydroxyapatite bone substitute is medically necessary for middle ear surgery.

    ALL of the following

    • Hydroxyapatite bone substitute is used for middle ear surgery.

    Beta Tri-Calcium Phosphate-Based Bone Graft Products

    Beta tri-calcium phosphate (b-TCP)-based bone graft extenders and substitutes are medically necessary for spinal fusions.

    ALL of the following

    • Beta tri-calcium phosphate (b-TCP)-based bone graft extender or substitute is used.
    • The procedure is a spinal fusion.

    Infuse® Bone Graft is experimental and investigational for all other indications, including its use in ankle fusions and cervical fusions, because its effectiveness for indications other than the ones listed above has not been established.

    SummaCare considers all other bone and tendon graft substitutes experimental and investigational because there is insufficient evidence to support their use for these indications.

    Coding and Operational Thresholds

    CPT Codesmixed
    20930Allograft for spine surgery only; morselized.
    20931Allograft for spine surgery only; structural.
    20939Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure).
    C1762Connective tissue, human (includes fascia lata).
    C9359Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Putty, Integra OS Osteoconductive Scaffold Putty), per 0.5 cc; porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Strip), per 0.5 cc.
    0707TInjection(s), bone substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization.
    11981Insertion, non-biodegradable drug delivery implant.
    11982Removal, non-biodegradable drug delivery implant.
    11983Removal with reinsertion, non-biodegradable drug delivery implant.
    Multilevel spinal fusion
    TermMultilevel spinal fusion
    Qualifying threshold3 or more spinal motion segments
    Applicable procedurePosterolateral lumbar fusion, posterior lumbar interbody fusion, or transforaminal lumbar interbody fusion
    rhBMP-2 application for acute open tibial shaft fracture
    TermrhBMP-2 application for acute open tibial shaft fracture
    Application deadlineWithin 14 days of the fracture
    Required fixation

    Authorization and Documentation Requirements

    Prior Authorization

    Submit medical-necessity support

    For authorization, submit the planned procedure, graft or substitute product, and clinical information demonstrating that the applicable medical-necessity criteria are met. For Infuse rhBMP-2, document the procedure-specific indication, associated approved fusion when required, contraindication status, and the qualifying high-risk fusion-failure factors or tibial-fracture timing and fixation requirements.

    Denial Risk

    Avoid unlisted Infuse indications

    Infuse Bone Graft is experimental and investigational for indications other than the specifically listed procedures, including use in ankle fusions and cervical fusions outside the covered criteria. Authorization may be denied when the planned use does not meet a listed indication and all applicable criteria.

    Clinical Background

    Osteogenic proteins, also called bone morphogenetic or morphogenic proteins, are bone-matrix polypeptides that can induce cellular events leading to new bone formation. Bone and biologic allograft materials may be used as substitutes to promote spinal fusion, support incorporation of metal implants, improve autograft or allograft performance, or address osteochondral defects.

    Key Terms

    Osteogenic proteins / bone morphogenetic proteins
    Also calledBone morphogenetic or morphogenic proteins (BMPs)
    DefinitionA family of bone-matrix polypeptides isolated from a variety of mammalian species
    Bone-forming functionImplantation induces cellular events that lead to the formation of new bone
    Biologic allograft materials
    DefinitionBiologic graft materials used as bone graft substitutes
    Bone-based materialsAllografts made from bone
    Additional components
    Policy Summary
    PayerSummaCare
    PolicyBone and Tendon Graft Substitutes Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionFor authorization, submit the planned procedure, graft or substitute product, and clinical information demonstrating that the applicable medical-necessity criteria are met.
    SourceLink
    On This Page
    Covered Services and Medical NecessityCoding and Operational ThresholdsAuthorization and Documentation RequirementsClinical BackgroundKey Terms
    High risk for fusion failure using traditional autogenous bone grafting in a thoracolumbar fusion for correction of spinal deformity performed at more than one level.
  1. High risk for fusion failure using traditional autogenous bone grafting in a multi-level spinal fusion (i.e., 3 or more spinal motion segments).
  2. High risk for fusion failure using traditional autogenous bone grafting in a long posterior fusion to the sacrum in an adult individual undergoing correction or stabilization of spinal deformity.
  3. High risk for fusion failure using traditional autogenous bone grafting in a single-level lumbar or lumbosacral fusion, with or without interbody, when there is Meyerding Grade III or greater spondylolisthesis.
  4. High risk for fusion failure using traditional autogenous bone grafting due to ONE or more of the following metabolic or other conditions

    • Current smoker
    • Insulin diabetic with poor glycemic control
    • Chronic renal disease
    • Alcohol use disorder (AUD)
    • Corticosteroid dependence
    • Neuromuscular scoliosis
  5. Traditional autogenous bone graft is not available, is inadequate in volume, or is of poor quality due to ONE or more of the following

    • Rheumatoid arthritis
    • Osteoporosis
    • Trauma with concomitant pelvic injury
    • Individual at high risk for post-harvest iliac crest fracture
  6. Fracture stabilized with intramedullary nail fixation
    Denial Risk

    Verify graft-substitute coverage

    Bone and tendon graft substitutes not specifically identified as medically necessary are considered experimental and investigational because insufficient evidence supports their use for those indications. Verify that the planned product and indication fall within a specifically covered category before requesting authorization.

    Allografts containing stem cells or other materials besides bone
    Combined materialsA combination of bone with other materials
    rhBMP-2 / Infuse Bone Graft
    AbbreviationrhBMP-2
    DefinitionRecombinant human bone morphogenetic protein-2
    Marketed productInfuse Bone Graft (InFuse)